MacroGenics, Inc. (MGNX)
Nasdaq · Healthcare · Biotechnology
$3.77+5.31%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $240M
- 52-week range
- $1.29 – $5.08
- 52-week change
- +108.14%
- EPS (trailing)
- −$1.70
- Analyst rating
- 2.3 Buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $150M (−0.31%)
- Net income
- −$75K
- Operating margin
- −48.7%
- Diluted EPS
- −$1.18
- Free cash flow
- −$83.0M
From the company’s annual report on SEC EDGAR.
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc.
Headquarters: Rockville, United States · 293 employees · macrogenics.com